This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences practice is dedicated to providing tailored solutions to help maximize value and drive towards equitable access to life-saving treatments.
1 in 4 people globally are already affected by NCDs. By 2030, NCDs will cause 55 million deaths per year under ‘business as usual.’1,2 Effective...
Given the complexity of diagnosing rare disease patients, identifying real-world prevalence rates is difficult, as ranges from academic literature are often...
CRA is a proud sponsor of the event covering divisional patent strategies, denigration, Article 102, enforcement, mergers, distribution, as well as...
Tunahan Kirabali is a speaker during the webinar about sex and gender differences in the Alzheimer’s patient journey highlighting implications for clinical...
